Statin Therapy
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you your search results in order of date.
8808 records returned
Dithering over statins' side-effects label finally ends
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The pharmaceutical industry has taken almost two years to disseminate important informationOnce your medicines regulator decides it should change the side-effect warnings contained in the patient information of a drug taken by millions of people, how long do you think it would take for that change to be implemented?In February 2008 the Medicines and Healthcare Products Regulatory Agency (MHRA) published Drug Safety Update, Volume 1, Issue 7 (a boring government document). After a review of clinical trial data, spontaneous reports of suspected adverse drug reactions, and published literature, the agency concluded: "Product ...
Source: Guardian Unlimited Science - November 21, 2009 Category: Science Authors: Ben Goldacre Tags: Science Health Society Heart and circulation problems in diabetes Life and style UK news The Guardian Comment Comment is free Source Type: news
Prostate specific antigen levels reduced by statin therapyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Study results show that statin use reduces prostate-specific antigen levels in patients with prostate cancer. (Source: MedWire News - Lipidology)
Source: MedWire News - Lipidology - November 20, 2009 Category: Lipidology Source Type: news
Managing Mixed Dyslipidemia in Special PopulationsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Controlling low-density lipoprotein cholesterol is one of the major focuses of cardiovascular care. However, the twin global pandemics of obesity and diabetes are promoting an increased prevalence of associated cardiometabolic risk factors. These factors include mixed dyslipidemia, which is prevalent among several important subgroups of the overall population. Cardiovascular risk increases as women reach and extend beyond menopause, partly reflective of dyslipidemia. In addition, women with polycystic ovary syndrome display a cluster of risk factors reminiscent of the metabolic syndrome. Certain ethnic groups are also at i...
Source: Preventive Cardiology - November 20, 2009 Category: Cardiology Authors: Michael Miller Source Type: journals
Statins 'cut cardiovascular risk in healthy women'Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Taking statins could cut the risk of cardiovascular events among healthy women with no signs of established heart disease, the latest sub-analysis of the JUPITER trial shows. (Source: HealthcareRepublic Independent Nurse News)
Source: HealthcareRepublic Independent Nurse News - November 20, 2009 Category: Nursing Source Type: news
Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failureEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion
These findings suggest that hydrophilic rosuvastatin but not lipophilic simvastatin increases adiponectin and decreases HbA1c levels in patients with NICHF. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - November 19, 2009 Category: Cardiology Authors: Tsutamoto, T., Yamaji, M., Kawahara, C., Nishiyama, K., Fujii, M., Yamamoto, T., Horie, M. Tags: TREATMENT Source Type: journals
Vitamin B Niacin Offers No Additional Benefit to Statin Therapy in Seniors Already Diagnosed with Coronary Artery Disease-11/17/09Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. (Source: Johns Hopkins Medicine News)
Source: Johns Hopkins Medicine News - November 19, 2009 Category: Research Source Type: news
AHA: While on statins, better to also raise HDL and not just lower LDL levelsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Orlando, Fla.—The use of statins to reduce LDL-C is more effective with the subsequent addition of extended-release niacin (Niaspan; Abbott), which lowers LDL plus increases HDL, compared with the subsequent administration of ezetimibe (Zetia; Merck) in reducing the progression of atherosclerosis, according to the ARBITER 6-HALTS trial presented Monday at the American Heart Association (AHA) conference. (Source: Cardiovascular Business News)
Source: Cardiovascular Business News - November 19, 2009 Category: Cardiology Tags: Latest News Source Type: news
Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Objectives: The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) determined that treatment with amlodipine, lisinopril, or doxazosin was not superior to thiazide-like diuretic (chlorthalidone) in preventing coronary heart disease (CHD) or other cardiovascular events. This subanalysis examines baseline prevalence and in-trial incidence of new-onset atrial fibrillation (AF) or atrial flutter (AFL) and their influence on clinical outcomes.Background: Limited information is available on whether atrial fibrillation incidence is affected differentially by different classes of antihypertensive ...
Source: Journal of the American College of Cardiology - November 19, 2009 Category: Cardiology Authors: L. Julian Haywood, Charles E. Ford, Richard S. Crow, Barry R. Davis, Barry M. Massie, Paula T. Einhorn, Angela Williard, ALLHAT Collaborative Research Group Tags: QUARTERLY FOCUS ISSUE: HEART RHYTHM DISORDERS Source Type: journals
Statins protect women from heart diseaseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Study shows statins protect women from heart disease as well as men (Source: BHF National News)
Source: BHF National News - November 19, 2009 Category: Cardiology Source Type: consumer
Statins 'halve risk of heart attack in healthy women'Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Statins can halve the risk of cardiovascular disease in women who would not normally be considered for treatment, says a recent analysis. (Source: Pulse Today Clinical Updates)
Source: Pulse Today Clinical Updates - November 19, 2009 Category: Primary Care Tags: Picture stories Source Type: info
Statins 'halve risk of heart attack in healthy women'Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Statins can halve the risk of cardiovascular disease in women who would not normally be considered for treatment, says a recent analysis. (Source: Pulse)
Source: Pulse - November 19, 2009 Category: Primary Care Tags: News Source Type: news
Vitamin B Niacin Offers No Additional Benefit To Statin Therapy In Seniors Already Diagnosed With Coronary Artery DiseaseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 19, 2009 Category: Consumer Health News Tags: statins Source Type: news
Vitamin B Niacin Offers No Additional Benefit To Statin Therapy In Seniors Already Diagnosed With Coronary Artery DiseaseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. (Source: Cardiovascular / Cardiology News From Medical News Today)
Source: Cardiovascular / Cardiology News From Medical News Today - November 19, 2009 Category: Cardiology Tags: statins Source Type: news
Targeting Matrix Metalloproteinases in Inflammatory Conditions.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The matrix metalloproteinases (MMPs) and their endogenous regulators, the tissue inhibitors of MMPs (TIMPs) are responsible for the physiological remodelling of the extracellular matrix (ECM) in healthy connective tissues. MMPs are also involved in the regulation of cell behaviour via the release of growth factors and cytokines from the substrates they cleave, increasing the magnitude of their effects. Excess MMP activity is associated with ECM destruction in various inflammatory conditions, such as osteoarthritis (OA), while MMP under-activity potentially impairs healing by promoting fibrosis and preventing the effect...
Source: Current Drug Targets - November 19, 2009 Category: Drugs & Pharmacology Authors: Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A Tags: Curr Drug Targets Source Type: journals
Pfizer submits new paediatric data for atorvastatin to European Medicines AgencyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: BioSpace
Area: News
Pfizer Inc has announced that it has submitted paediatric data for atorvastatin to the European Medicines Agency (EMEA) and also developed a new chewable form of the drug, including a paediatric-appropriate 5 mg dose, which is part of this submission. (Source: NeLM - Cardiovascular Medicine)
Source: NeLM - Cardiovascular Medicine - November 19, 2009 Category: Cardiology Source Type: organizations
Pfizer Submits New Pediatric Data For Lipitor(R) (Atorvastatin) To The European Medicines Agency (EMEA)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 18, 2009 Category: Consumer Health News Tags: Pediatrics / Children's Health Source Type: news
Pfizer Submits New Pediatric Data For Lipitor(R) (Atorvastatin) To The European Medicines Agency (EMEA)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission. (Source: Cholesterol News From Medical News Today)
Source: Cholesterol News From Medical News Today - November 18, 2009 Category: Cardiology Tags: Pediatrics / Children's Health Source Type: news
Cardiovascular Outcomes with Ezetimibe and Simvastatin Similar to Statin Alone, Claims Data SuggestEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Retrospective Analysis of Almost 30,000 Patients Shows No
Significant Difference in Risk of Heart Attack or Stroke with
Monotherapy Compared With Combination Therapy
IRVINE, Calif.--(BUSINESS WIRE)--Nov 18, 2009 - Prescription
Solutions, a leading... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Niacin Not Beneficial in Patients at Goal With Statins: NIA PlaqueEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The addition of niacin to statin therapy in secondary-prevention patients resulted in a significant improvement in lipids but failed to significantly alter atherosclerotic disease progression as measured by MRI. Researchers say it's a win for treating patients to target and suggest this trumps raising HDL. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 18, 2009 Category: Consumer Health News Tags: Cardiology Source Type: news
Statins Do Not Eliminate Risk of Low HDL-Cholesterol LevelsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Researchers say a new study shows that statins don't alter the risks associated with low HDL-cholesterol levels and that raising HDL cholesterol 10 mg/dL could prevent an additional eight MIs per 1000 patient-years. Heartwire (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - November 18, 2009 Category: Universities & Medical Training Tags: Cardiology Source Type: info
Statins may benefit "healthy" womenEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Women with normal cholesterol levels could still benefit by taking a statin, a study shows (Source: Nursing in Practice)
Source: Nursing in Practice - November 18, 2009 Category: Nursing Source Type: news
Niacin Adds No Benefit for Statin Patients: StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Taking the B vitamin didn't reverse or stall carotid artery disease (Source: Forbes.com Health News)
Source: Forbes.com Health News - November 18, 2009 Category: Consumer Health News Source Type: news
Niacin not beneficial in patients at goal with statins: NIA PlaqueEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The addition of niacin to statin therapy in secondary-prevention patients resulted in a significant improvement in lipids but failed to significantly alter atherosclerotic disease progression as measured by MRI. Researchers say it's a win for treating patients to target and suggest this trumps raising HDL. (Source: theHeart.org)
Source: theHeart.org - November 18, 2009 Category: Cardiology Source Type: info
Niacin Adds No Benefit for Statin PatientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Taking the B vitamin didn't reverse or stall carotid artery disease Source: HealthDay
Related MedlinePlus Topics: Coronary Artery Disease, Statins, Vitamins (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 18, 2009 Category: Consumer Health News Source Type: consumer
The COACH Program Produces Sustained Improvements in Cardiovascular Risk Factors and Adherence to Recommended Medications—Two Years Follow-upEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion: The changes in CRF status and adherence to cardiac medications achieved at 6 months in The COACH Program are sustained for at least 18 months after cessation of The COACH Program. (Source: Heart, Lung & Circulation)
Source: Heart, Lung & Circulation - November 18, 2009 Category: Cardiology Authors: Michael Jelinek, Margarite J. Vale, Danny Liew, Leeanne Grigg, Anthony Dart, David L. Hare, James D. Best Tags: Original Articles Source Type: journals
Pfizer Inc Submits New Pediatric Data for Lipitor to EMEAEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
From EquityBites (November 18, 2009)
Health care company Pfizer Inc (NYSE:PFE) declared on Wednesday the
submission of paediatric data for Lipitor (atorvastatin) to the
European Medicines Agency (EMEA).
This follows the EMEA's conclusion that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2009 Category: Pharmaceuticals Source Type: news
Drug can halve heart attacks in the healthy: Statins give 'unprecedented' cut in risk, say doctorsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A drug has been found to cut the risk of heart attacks by almost half in 'healthy' people, researchers say today. (Source: the Mail online | Health)
Source: the Mail online | Health - November 18, 2009 Category: Consumer Health News Source Type: news
LDL cholesterol dropping in U.S. adultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A study credits statins for lower levels since 1999 but notes that too many people are going untreated for the 'bad' cholesterol. Some say simpler treatment guidelines are needed.
Levels of LDL, or "bad," cholesterol fell by about a third from 1999 to 2006 among American adults, a study has found -- probably because of the influence of statin drugs on blood lipid levels. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - November 18, 2009 Category: Science Source Type: news
Niacin Adds No Benefit for Statin Patients: StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Title: Niacin Adds No Benefit for Statin Patients: StudyCategory: Health NewsCreated: 11/18/2009 8:10:00 AMLast Editorial Review: 11/18/2009 (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - November 18, 2009 Category: Cardiology Source Type: consumer
Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Pre-eclampsia, a pregnancy-specific multi-organ syndrome characterized by widespread endothelial damage, is a new risk factor for cardiovascular disease. No therapies exist to prevent or treat this condition, even to achieve a modest improvement in pregnancy length or birth weight. Co-administration of soluble VEGFR-1 [VEGF (vascular endothelial growth factor) receptor-1; more commonly known as sFlt-1 (soluble Fms-like tyrosine kinase-1)] and sEng (soluble endoglin) to pregnant rats elicits severe pre-eclampsia-like symptoms. These two anti-angiogenic factors are increased dramatically prior to the clinical onset of pr...
Source: Biochemical Society Transactions - November 18, 2009 Category: Biochemistry Authors: Ahmed A, Cudmore MJ Tags: Biochem Soc Trans Source Type: journals
Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CADEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Johns Hopkins Medical Institutions) The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 18, 2009 Category: Global & Universal Source Type: news
Apolipoprotein E Genotype, Plasma Cholesterol, and Cancer: A Mendelian Randomization StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Observational studies have shown an association between low plasma cholesterol levels and increased risk of cancer, whereas most randomized clinical trials involving cholesterol-lowering medications have not shown this association. Between 1997 and 2002, the authors assessed the association between plasma cholesterol levels and cancer risk, free from confounding and reverse causality, in a Mendelian randomization study using apolipoprotein E (ApoE) genotype. ApoE genotype, plasma cholesterol levels, and cancer incidence and mortality were measured during a 3-year follow-up period among 2,913 participants in the Prospective...
Source: American Journal of Epidemiology - November 18, 2009 Category: Epidemiology Authors: Trompet, S., Jukema, J. W., Katan, M. B., Blauw, G. J., Sattar, N., Buckley, B., Caslake, M., Ford, I., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M. Tags: RESEARCH-ARTICLE Source Type: journals
Role of Tissue Factor in the Maternal Immunological Attack of the Embryo in the Antiphospholipid SyndromeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Recurrent fetal loss affects 1–5% of women of childbearing age. Immunological mechanisms may account for 40% of recurrent
miscarriages, and in particular, the antiphospholipid syndrome (APS) appears to be implicated in 7–25% of the cases. Because
antiphospholipid (aPL) antibodies have thrombogenic properties, fetal loss in patients with APS has been ascribed to thrombosis
of placental vessels. However, we have shown that inflammation, specifically activation of complement with generation of the
anaphylotoxin C5a, is an essential trigger of fetal injury. Thrombosis and inflammation are linked in ...
Source: Clinical Reviews in Allergy and Immunology - November 18, 2009 Category: Allergy & Immunology Tags: Clinical Reviews in Allergy and Immunology Source Type: journals
Statins in the Management of Patients with Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions: Existing RCTs suggest that statins reduce DINDs, with a possible trend toward lower mortality. These findings are not supported
by observational research. Although not assessed in all studies, current data do not indicate that statins improve neurological
outcomes.
Content Type Journal ArticleCategory Review ArticleDOI 10.1007/s12028-009-9306-9Authors
Andreas H. Kramer, University of Calgary Departments of Critical Care Medicine and Clinical Neurosciences, Hotchkiss Brain Institute Foothills Medical Center, Room EG23J, 1403 29th St. N.W. Calgary AB T2N 2T9 CanadaJeffrey J. Fletcher, University of Michig...
Source: Neurocritical Care - November 18, 2009 Category: Neurology Tags: Neurocritical Care Source Type: journals
Restenosis after carotid endarterectomy: significance of newly acquired risk factorsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion: CRFs acquired during long-term follow-up after CEA may independently contribute to progressive ICA stenosis after endarterectomy. Newly acquired CRFs might be more hazardous than CRFs present prior to CEA. (Source: European Journal of Neurology)
Source: European Journal of Neurology - November 18, 2009 Category: Neurology Authors: F. Fluri, F. Hatz, B. Voss, P. A. Lyrer, S. T. Engelter Source Type: journals
Statin use can lower PSA levelEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Prostate cancer patients who take statins have lower prostate-specific antigen levels than men who do not take the medication, but present with more aggressive stages of disease, study findings show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 18, 2009 Category: Cancer & Oncology Source Type: news
Journal Scan: Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness (N Engl J Med 2009;Nov 15:[Epub ahead of print].)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In the ARBITER 6-HALTS trial, patients with coronary heart disease or a coronary heart disease risk equivalent, who were receiving long-term statin therapy, with a low-density lipoprotein (LDL) cholesterol under 100 mg/dl and a high-density lipoprotein (HDL) cholesterol under 50 mg/dl for men or 55 . . . (Source: Cardiosource)
Source: Cardiosource - November 18, 2009 Category: Cardiology Source Type: organizations
Commentary: Primary prevention of cardiovascular diseaseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: JAMA
Area: News
In this commentary, the author discusses different approaches to the primary prevention of cardiovascular disease (CVD), now that the cost of statins has decreased and there is a large amount of data available on their efficacy and safety. They ask whether "for an inexpensive treatment, known to be safe and effective, should the eligibility be widened?" They also ask what the consequences of the new vascular checks - a 'systematic risk-based approach' - are, and how they compare with alternatives.
They conclude that "scant information is available on the cost and the public a...
Source: NeLM - News - November 18, 2009 Category: Drugs & Pharmacology Source Type: organizations
Phase III data for mipomersen in homozygous familial hypercholesterolemia presented at conferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: BioSpace
Area: News
BioSpace has reported on the findings of a Phase III study of adding mipomersen to lipid-lowering therapy in patients with homozygous familial hypercholesterolemia (hoFH), presented at the American Heart Association's Scientific Sessions.
The trial randomised 51 patients (aged ?12 years) with hoFH to double-blind treatment with mipomersen (200mg) or placebo weekly for 26 weeks. All but one of the patients (98%) were already being treated with lipid-lowering therapy, including a statin alone (22%), or in combination with at least one other lipid-lowering agent (78%; ezetimibe in 74% o...
Source: NeLM - News - November 18, 2009 Category: Drugs & Pharmacology Source Type: organizations
Statin use can lower PSA levelEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Prostate cancer patients who take statins have lower prostate-specific antigen levels than men who do not take the medication, but present with more aggressive stages of disease, study findings show. (Source: MedWire News - Prostate Cancer)
Source: MedWire News - Prostate Cancer - November 18, 2009 Category: Cancer & Oncology Source Type: news
Incidence of High Cholesterol Drops in U.S.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Down by 30 percent, but those with high levels often don't know it, study finds Source: HealthDay
Related MedlinePlus Topics: Cholesterol, Health Screening, Statins (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 17, 2009 Category: Consumer Health News Source Type: consumer
Statins do not eliminate risk of low HDL-cholesterol levelsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Researchers say a new study shows that statins don't alter the risks associated with low HDL-cholesterol levels and that raising HDL cholesterol 10 mg/dL could prevent an additional eight MIs per 1000 patient-years. (Source: theHeart.org)
Source: theHeart.org - November 17, 2009 Category: Cardiology Source Type: info
NicOx - NCX 6560 meets primary and secondary objectives in first-in-man studyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Sophia Antipolis, France, November 13, 2009 - NicOx S.A. (NYSE
Euronext Paris: COX) today announced that a phase 1b, first-in-man
study for NCX 6560, versus placebo and Lipitor® (atorvastatin),
has met its primary and secondary objectives. The... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Heart Experts Say Early End To Key Study On Benefits Of Niacin, A B Vitamin, In Keeping Arteries Open Was PrematureEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 17, 2009 Category: Consumer Health News Tags: Complementary Medicine / Alternative Medicine Source Type: news
Heart Experts Say Early End To Key Study On Benefits Of Niacin, A B Vitamin, In Keeping Arteries Open Was PrematureEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Cardiovascular atherosclerosis, as it is also known, is believed responsible for one in three deaths in the United States each year. (Source: Cardiovascular / Cardiology News From Medical News Today)
Source: Cardiovascular / Cardiology News From Medical News Today - November 17, 2009 Category: Cardiology Tags: Complementary Medicine / Alternative Medicine Source Type: news
When will medics make up their minds?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
IT IS impossible to know what to believe. What is safe and effective one week can put your life at risk the next. Some drugs, such as statins, can save countless lives but they can also have nasty side effects. The resulting confusion can make it difficult to judge what's safe and what isn't. Read our A to Z guide to conflicting health advice: (Source: Daily Express - Health)
Source: Daily Express - Health - November 17, 2009 Category: Consumer Health News Source Type: news
The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk (December).Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSIONS: Overall, the evidence to date suggests that administration of ezetimibe, either as monotherapy or in combination with a statin, exerts minimal beneficial effects on endothelial function and other ancillary measures of cardiovascular disease risk beyond those conferred by its cholesterol-lowering effects. Studies with larger sample sizes and follow-up beyond 12 weeks remain necessary to further define the impact of ezetimibe on the processes integral to the pathogenesis and progression of cardiovascular disease.
PMID: 19920161 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 17, 2009 Category: Drugs & Pharmacology Authors: Bass A, Hinderliter AL, Lee CR Tags: Ann Pharmacother Source Type: journals
Does Simvastatin Cause More Myotoxicity Compared with Other Statins? (December).Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSIONS: Overall, the rates of severe myotoxicity with all statins are low, especially with low-to-moderate doses. However, recent trials for those using simvastatin 80 mg daily suggest a higher incidence of myotoxicity compared with maximum approved doses of other statins. Practitioners should be aware of these possible risks and individualize therapy to limit myotoxicity.
PMID: 19920157 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 17, 2009 Category: Drugs & Pharmacology Authors: Backes JM, Howard PA, Ruisinger JF, Moriarty PM Tags: Ann Pharmacother Source Type: journals
Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This study is focused on utilizing human embryonic kidney (HEK) 293 cell cultures genetically transfected with the human organic anion transporting polypeptides (OATP) 1B1 transporter to identify substrates and inhibitors in drug development. The kinetics of OATP1B1-mediated uptake of [(3)H]-oestradiol 17beta-glucuronide and inhibition of uptake by rifamycin SV were used to determine K(m), V(max), and IC(50) values over a range of passage numbers to investigate accuracy and precision. The mean K(m) and V(max) values were found to be 6.3 +/- 1.2 muM and 460 +/- 96 pmol min(-1) mg(-1), respectively. The mean IC(50) value for...
Source: Xenobiotica - November 17, 2009 Category: Research Authors: Sharma P, Holmes VE, Elsby R, Lambert C, Surry D Tags: Xenobiotica Source Type: journals
Role of Cellular Cholesterol in Pharmacologic Preconditioning with Cyclosporine in Experimental Kidney Transplantation.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion: CsA preconditioning leads to better outcomes in kidney transplantation and is associated with up-regulation of renal FC content. The latter may then contribute to acquired cytoresistance, possibly by stabilizing the plasma membrane. Thus, use of statins around the time of transplantation may need to be evaluated until further studies are conducted to determine the clinical relevance of this observation.
PMID: 19923799 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 17, 2009 Category: Urology & Nephrology Authors: Shihab FS, Bennett WM, Andoh TF Tags: Am J Nephrol Source Type: journals
